Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 28:13:98.
doi: 10.4103/abr.abr_202_23. eCollection 2024.

Effectiveness of Extended-Release Bupropion and Duloxetine on Pelvic Pain and Sexual Function among Patients with Chronic Prostatitis/Chronic Pelvic Pain

Shokufe Jaafari  1 , Mitra Molaeinezhad  2 , Mohammad J Tarrahi  3 , Mohsen R Moosaei  4 , Katayoun Sahfiei  1 , Hamid Afshar  5
Affiliations

Effectiveness of Extended-Release Bupropion and Duloxetine on Pelvic Pain and Sexual Function among Patients with Chronic Prostatitis/Chronic Pelvic Pain

Shokufe Jaafari et al. Adv Biomed Res. .

Abstract

Background: This study aimed to compare the efficacy of the two antidepressants, duloxetine and bupropion, on pelvic pain in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

Materials and methods: This single-blind clinical trial was conducted on 68 CP/CPPS patients. The patients with CP/CPPS received either an extended-release formulation of 150 mg/day bupropion (bupropion group) or duloxetine 30 mg/day for 12 weeks (duloxetine group). The pain, depression (using the Hospital Anxiety and Depression Scale (HADS)), quality of life (QoL), and sexual dysfunction scores were evaluated and compared before the intervention and after 4, 12, and 16 weeks of intervention in both groups.

Results: The pain score in the duloxetine group was significantly lower than the bupropion group after 12 and 16 weeks of intervention (P value <0.05). The mean HADS and QoL scores at baseline and after 4, 12, and 16 weeks of intervention had insignificant differences between the two groups (P value >0.05) but improved in both groups. After 4 and 12 weeks of intervention, sexual dysfunction scores in the duloxetine group were higher than those in the bupropion group (P value <0.05).

Conclusions: Depression and anxiety scores were significantly reduced in both groups. Sexual function was improved in the bupropion group compared with the duloxetine group, while pain scores improved significantly in the duloxetine group. Therefore, proposing the appropriate treatment based on the experienced complications of CP/CPPS is the key element of the management of these patients; however, further studies are required to compare the long-term effects of these two regimens on CP/CPPS patients' concerns.

Keywords: Bupropion; chronic prostatitis with chronic pelvic pain syndrome; depression; duloxetine; pain; quality of life; sexual function.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Consort flowchart
Figure 2
Figure 2
Mean decrease in VAS and pain scores between the two groups at the beginning, fourth, twelfth, and 16 weeks of the study. C1: Changes in mean VAS and pain scores after a 4-week intervention. C2: Changes in mean VAS and pain scores after a 12-week intervention. C3: Changes in the mean VAS and pain scores after a 16-week intervention
Figure 3
Figure 3
Mean changes in anxiety and depression scores between the two at the beginning, fourth, twelfth, and 16 weeks of the study. C1: Changes in mean anxiety and depression scores after 4 weeks. C2: Changes in mean anxiety and depression scores after 12 weeks. C3: Changes in mean anxiety and depression scores after 16 weeks
Figure 4
Figure 4
Mean changes in sexual function and quality-of-life scores between the two groups at the beginning, fourth, twelfth, and 16 weeks of the study. C1: Changes in the means of sexual function and quality-of-life scores at 4 weeks after the intervention. C2: Changes in the means of sexual function and quality-of-life scores at 12 weeks after the intervention. C3: Changes in the means of sexual function and quality-of-life scores at 16 weeks after the intervention
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhang J, Liang C, Shang X, Li H. Chronic prostatitis/chronic pelvic pain syndrome: A disease or symptom? Current perspectives on diagnosis, treatment, and prognosis. Am J Mens Health. 2020;14:1557988320903200. - PMC - PubMed
    1. Evans-Durán B, Tripp DA, Campbell J, Doiron RC, Nickel JC. Chronic prostatitis/chronic pelvic pain syndrome-related pain symptoms and their impact on sexual functioning. Canad Urol Assoc J. 2022;16:222–7. - PMC - PubMed
    1. Li HJ, Kang DY. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: A meta-analysis. World J Urol. 2016;34:1009–17. - PMC - PubMed
    1. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome. Drugs Aging. 2021;38:845–86. - PubMed
    1. DeWitt-Foy ME, Nickel JC, Shoskes DA. Management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Focus. 2019;5:2–4. - PubMed

LinkOut - more resources